Hospital

Pharmacists can play an important role in tobacco cessation.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

USP provides health literacy standards and solutions that enhance medication safety and improve patient outcomes.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

Stem cell transplantation rates increased the longer patients remained on therapy for myelofibrosis.

Vusolimogene oderparepvec in combination with nivolumab is being assessed to treat individuals with unresectable or metastatic stage IIIb-IV cutaneous melanoma.

The caps on insulin and yearly out-of-pocket drug costs remain unaffected by this decision.

Regardless of confounding factors, the ratio of high-sensitivity C-reactive protein to high-density lipoprotein cholesterol predicts the all-cause long-term mortality.

An infusion and specialty clinical pharmacist is a valuable integrated member of the health care team as demonstrated by cost avoidance and high satisfaction reported by both veterans and specialty providers.

Pharmacists play a significant role in managing gout by educating patients about the disease and ensuring proper medication adherence to urate-lowering therapy.

Pharmacists ensure responsible antibiotic use, combating resistance through tailored therapies.

At the start of 2025, 590 drug prices changed, with only 7 drugs seeing decreases in wholesale acquisition costs (WAC).

A series of patient cases demonstrates the potential harm that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may face when transitioning from intravenous immunoglobulin (IVIG) to FcRn therapy.

The international cohort study evaluated the safety, efficacy of BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel.

Investigators found that the polypill treatment improved cardiovascular disease and lowered health care costs.

KN026 is a humanized bispecific antibody that targets and binds to HER2 proteins on the surface of cancer cells.

Esketamine targets glutamate, the most abundant neurotransmitters in the brain.

As H5N1 bird flu outbreaks impact all 50 states, concerns grow over its spread to humans.

Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, discusses the pharmacists role in diabetes care.

The closure of Baxter’s North Cove facility has significantly impacted existing IV fluid shortages into 2025.

The authors found that humidity, cold and heat waves, and air pollution led to a higher likelihood of asthma- and chronic obstructive pulmonary disease (COPD)-related hospitalizations.

The reduction in cardiovascular end points and the increase in adverse events observed in a clinical trial were largely transportable to trial-eligible chronic kidney disease (CKD) populations from clinical practice.